[1] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南 (2019年版). 中华肝脏病杂志, 2019, 27: 938-961.
[2] Hou J, Chen W, Han Y, et al. Increasing age and comorbidities in Chinese urban patients with chronic hepatitis B from 2013 to 2016: A retrospective claims data analysis. The 28th Annual Conference of Asian Pacific Association for the Study of the Liver, Manila, Phillipines, Feburary 20-24, 2019.
[3] Si J, Yu C, Guo Y, et al. Chronic hepatitis B virus infection and risk of chronic kidney disease: a population-based prospective cohort study of 0.5 million Chinese adults. BMC Med, 2018, 16: 93.
[4] Du Y, Zhang S, Hu M, et al. Association between hepatitis B virus infection and chronic kidney disease: A cross-sectional study from 3 million population aged 20 to 49 years in rural China. Medicine, 2019, 98: e14262.
[5] Chen YC, Su YC, Li CY, et al. 13-year nationwide cohort study of chronic kidney disease risk among treatment-naïve patients with chronic hepatitis B in Taiwan. BMC Nephrol, 2015, 16: 110.
[6] Hong Y S, Ryu S, Chang Y, et al. Hepatitis B virus infection and development of chronic kidney disease: a cohort study. BMC Nephrol, 2018, 19: 353.
[7] Nguyen M H, Lim JK, Burak Ozbay A, et al. Advancing age and comorbidity in a US insured population-based cohort of patients with chronic hepatitis B. Hepatology, 2019, 69: 959-973.
[8] Wang F, He K, Wang J, et al. Prevalence and risk factors for CKD: A comparison between the adult populations in China and the United States. Kidney Int Rep, 2018, 3: 1135-1143.
[9] Ning L, Lin W, Hu X, et al. Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey. J Viral Hepat, 2017, 24: 1043-1051.
[10] Wang H, Men P, Xiao Y, et al. Hepatitis B infection in the general population of China: A systematic review and meta-analysis. BMC Infect Dis, 2019, 19: 811.
[11] Baeg MK, Yoon SK, Ko SH, et al. Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys. Hepatol Int, 2016, 10: 470-477.
[12] Huang Z, Wei H, Cheng C, et al. Low bone mineral density in chronic hepatitis B virus infection: A case-control study. Pak J Med Sci, 2017, 33: 457-461.
[13] Chen CH, Lin CL, Kao CH. Association between chronic hepatitis B virus infection and risk of osteoporosis: A nationwide population-based study. Medicine, 2015, 94: e2276.
[14] Min C, Bang W J, Kim M, et al. The association between hepatitis and osteoporosis: a nested case-control study using a national sample cohort. Arch Osteoporos, 2019, 14: 34.
[15] 国家卫生健康委员会, 国家卫生健康委员会2018年10月19日媒体沟通会文字实录.(2018-10-19)[2020-01-18]. http://www.nhc.gov.cn/wjw/xwdt/201810/d816a5c72f6b45e399a1e7214642cd47.shtml.
[16] Liu A, Le A, Zhang J, et al. Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015. Clin Transl Gastroenterol, 2018, 9: 141.
[17] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J Hepatol, 2017, 67: 370-398.
[18] Terrault NA, Lok ASF, Mcmahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 2018, 67: 1560-1599.
[19] Kazanciogˇlu R. Risk factors for chronic kidney disease: An update. Kidney Int Suppl, 2013, 3: 368-371.
[20] Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. New Engl J Med, 2012, 367: 20-29.
[21] KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl, 2013, 3: 1-150.
[22] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol, 2019, 70: 172-193.
[23] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南( 2017). 中华骨质疏松和骨矿盐疾病杂志, 2017, 10: 413-443.
[24] Seto WK, Asahina Y, Brown TT, et al. Improved bone safety of tenofovir alafenamide compared to tenofovir disoproxil fumarate over 2 years in patients with chronic HBV infection. Clin Gastroenterol Hepatol, 2018.
[25] Udompap P, Kim D, Ahmed A, et al. Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment. Aliment Pharmacol Ther, 2018, 48: 1282-1289.
[26] Hwang HS, Park CW, Song MJ. Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection. Hepatology, 2015, 62: 1318-1320.
[27] Shan S, You H, Niu J, et al. Baseline characteristics and treatment patterns of the patients recruited to the China registry of Hepatitis B. J Clin Transl Hepatol, 2019, 7: 322-328.
[28] Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol, 2018, 68: 672-681.
[29] Lampertico P, Buti M, Fung S, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol, 2020, 5: 441-453.
[30] Janssen H, Lampertico P, Chen CY, et al. SAT429 - Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study. J Hepatol, 2020, 73: S866-S867. |
